Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2005-08-30
2005-08-30
Wang, Sheng Jun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S182000, C514S169000, C514S002600
Reexamination Certificate
active
06936599
ABSTRACT:
The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, more particularly, Th1-mediated (cell-mediated) autoimmune diseases including: multiple sclerosis (MS), rheumatoid arthritis (RA), autoimmune thyroiditis and uveitis. Most preferably the invention is used to treat a patient with a therapeutically effective amount of estriol of 8 milligrams once daily via oral administration to treat the symptoms or prevent the onset of multiple sclerosis.
REFERENCES:
patent: 5200197 (1993-04-01), Wright et al.
patent: 6013642 (2000-01-01), Foulkes et al.
patent: 6043236 (2000-03-01), Brattsand et al.
patent: WO 97/08188 (1997-03-01), None
patent: WO 01/85154 (2001-11-01), None
Abramsky O. Pregnancy and multiple sclerosis. Annals of Neurology 1994; 36 Suppl: S38-41.
Aharoni, R., Teitelbaum, D., Sela, M. & Amon, R. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. Journal of Neuroimmunology 1998; 91: 135-46.
Ando, D., Clayton, J., Kono, D., Urban, J., Sercarz, E.E., “Encephalitogenic T Cells in the B10.PL Model of Experimental Allergic Encephalomyelitis (EAE) Are of the Th1 Lymphokine Subtype,” Cell. Immunol., 124:132-143, 1989.
Asthana, S., Baker, L.D., Craft, S. et al. “High-Dose Estradiol Improves Cognition for Women with AD: Results of a Randomized Study,” Neurology, 2001;57:605-12.
Balashov, K.E., Comabella, M., Ohashi, T. et al. Defective regulation of IFNgamma and IL-12 by endogenous IL-10 in progressive MS. Neurology 2000; 55:192-8.
Barkhof, F., Van Waesberghe, J.H., Filippi, M. et al. T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. Brain 2001; 124:1396-402.
Barkley, M. S., B. L. Lasley, M. A. Thompson, and C. H. Shackleton. 1985. Equol: a contributor to enigmatic immunoassay measurements of estrogen. Steroids 46:587.
Bebo BF Jr.; Fyfe-Johnson A; Adlard K; Beam AG; Vandenbark AA: Offner H. Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains. Journal of Immunology, Feb. 1, 2001, 166(3):2080-9.
Becker, C.C., Gidal, B.E. and Fleming, J.O., “Immunotherapy in Multiple Sclerosis”, Amer. Journal of Health System Pharmacy, 52(19):2105-20, 1995, [Oct. 1].
Bijisma, J.W. and Van der Brink, H.R., “Estrogens and Rheumatoid Arthritis,” American Journal of Reproductive Immunology, 28:231-234, 1992.
Birk, K. et al., (1990) The Clinical Course of Multiple Sclerosis During Pregnancy and the Puerperium, Arch Neurol, 47, 738-42.
Birk, K., Smeltzer, S.C. and Rudick, R. (1998) Pregnancy and Multiple Sclerosis, Semin Neurol 8, 205-13.
Bongioanni, Durelli, Ferrero, Imperiale, Oggero, Verdun, Aimo, Pagni, Geuna, Bergamasco, “Systemic High-Dose Recombinant-alpha-2a-Interferon Therapy Modulates Lymphokine Producion in Multiple Sclerosis,” J. Neurolog. Sci., 143 (1-2):91-99, Nov., 1996.
Boothman, B.R., “Interferon Beta: The Current Position”, British Jour. of Hospital Medicine, 57(6):277-80, 1997, [Mar. 19-Apr. 1].
Boumpas, D.T., Fessler, B.J., Austin, H.A., Balow, J.E., Klippel, J.H., Lockshin, M.D., “Systemic Lupus Erythematosus: Emerging Concepts,” Annals of Internal Medicine, 123:42-53, 1995.
Brod, S.A. Lindsey, J.W. and Wolinsky, J.S., “Multiple Sclerosis: Clinical Presentation, Diagnosis and Treatment” Amer. Family Physician, 54(4):1301-6, 1309-11, 1996 [Sep. 15].
Brod, S.A., Marshall, Henninger, Sriram, Khan, Wolinsky, J.S., “Interferon-beta 1b Treatment Decreases Tumor Necrosis Factor-beta and Increases Interleukin-6 Production in Multiple Sclerosis,” Neurology, 46(6):1633-1638, Jun., 1996.
Brostoff and Gold, “Results of a Phase I Clinical Trial of a T-Cell Receptor Peptide Vaccine in Patients with Multiple Sclerosis. I. Analysis of T-Cell Receptor Utilization in CSF Cell Populations,” Journal of Neuroimmunologym 76(1-2):15-28, 1997, [Jun. ].
Cannella, B., Gao, Y.L., Brosnan, C. Raine, C.S., “IL-10 Fails to Abrogate Experimental Autoimmune Encephalomyelitis,” Journal of Neuroscience Research, 45:735-746, 1996.
Cardozo, L., Rekers, H., Tapp, A., Barnick, C., Shepherd, A., Schussler, B., Kerr-wilson, R., Van Geelan, J., Barlebo, H., and Walter, S., “Oestriol in the Treatment of Postmenopausal Urgency: A Multicentre Study,” Maturitas, 18(1):47-53, Dec. 1993.
Cheng, G., Liu, J., Zhang, Q., Fan, W., Ye, H., Wang, Z. and Pan, H., “Nylestriol Replacement Therapy in Postmenopausal Women,” Chinese Medical Journal, 106:911-916, 1993.
Comi, G., Filippi, M. & Wolinsky, J.S. European/Canadian multicenter, double-blind, randomized, placebo- controlled study of the effects of glatiramer acetate on magnetic resonance imaging—measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neuro 2001;49:290-7.
Confavreux, C., Hutchinson, M., Hours, M.M. et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group [see comments]. New England Journal of Medicine 1998; 339:285-91.
Correale, J., Arias, M. and Gilmore, W. Steroid hormone regulation of cytokine secretion by proteolipid protein-specific CD4+ T cell clones isolated from multiple sclerosis patients and normal control subjects. Journal of Immunology 1998; 161:3365-74.
Crisi, G.M., Santambrogio, L., Hochwald, G.M., Smith, S.R., Carlino, J.A. and Thorbecke, G.J., “Staphylcoccal Enterotoxin B and Tumor-Necrosis Factor-alpha-Induced Relapses of Experimental Allergic Encephalomyelitis: Protection by Transforming Growth Factor-Beta and Interleukin-10,” European Journal of Immunology, 25:3035-3040, 1995.
Da Silva, J.A. and Hall, G.M., “The Effects of Gender and Sex Hormones on Outcome in Rheumatoid Arthritis,” Baillieres Clinical Rheumatology, 6:196-219, 1992.
Da Silva, J.A. and Spector, T.D., The Role of Pregnancy in the Course and Aetiology of Rheumatoid Arthritis, Clinical Rheumatology, pp. 189-194, 1992.
Damek, D.M. & Shuster, E.A. Pregnancy and multiple sclerosis. Mayo Clinic Proceedings 1997; 72:977-89.
DeGroot, LJ. and Jameson, J.L., 1994. Endocrinology, vol. 3, Part 9, pp. 2171-2223.
Delassus, S., Coutinho, G.C., Saucier, C., Darche, S., Kourlisky, P., “Differential Cytokine Expression in Maternal Blood and Placenta During Murine Gestation,” J. Immunol., 152:2411-2420, 1994.
Drew, P.D. & Chavis, J.A. Female sex steroids: effects upon microglial cell activation. J Neuroimmunol 2000; 111:77-85.
Duda, P.W., Schmied, M.C., Cook, S.L. et al. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. Journal of Clinical Investigation 2000; 105:967-76.
Follingstad, A.H., et al., “Estriol, the Forgotten Estrogen?”JAMA, 239:29-30, 1978.
Fritzmeier, K.H., et al. (2001) Analysis of the Effects of ERbeta on ERalpha Transcriptional Activity Using Isotope Selective Ligands. Experimental and Clinical Endocrinology & Diabetes 109, S57.
Gilmore, W., Weiner, L.P. & Correale, J. Effect of estradiol on cytokine secretion by proteolipid protein-specific T cell clones isolated from multiple sclerosis patients and normal control subjects. Journal of Immunology 1997; 158:446-51.
Hall GM; Daniels M; Huskisson EC; Spector TD. A randomised controlled trial of the effect of hormone replacement therapy on disease activity in postmenopausal rheumatoid arthritis. Annals of the Rheumatic Diseases, Feb. 1994, 53(2):112-6. Pub type: Clinical Trial; Journal Article: Randomized Controlled Trial.
Harms, C., Lautenschlager, M., Bergk, A. et al. Differential mechanisms of neuroprotection by 17 beta-estradiol in apoptotic versus necrotic neurodegeneration. J Neurosci 2001; 21:2600-9.
Heman MA; Hohol MJ; Olek MJ; Speigelman D; Ascherio A. Oral contraceptives and the incidence of multiple sclerosis.
McDermott Will & Emery LLP
The Regents of the University of California
Wang Sheng Jun
LandOfFree
Estriol therapy for multiple sclerosis and other autoimmune... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Estriol therapy for multiple sclerosis and other autoimmune..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Estriol therapy for multiple sclerosis and other autoimmune... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3519130